Menu

Report Library

All Reports

Q3 2016 Outlook Report

July 06, 2016

In this report, we cover catalysts from 24 drugs, devices and diagnostics expected to occur in Q3 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q3 2016. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Q2 2016 Outlook Report highlighted several high- impact catalysts. The results of these catalysts can be found on Page 5 of this report. Biomedtracker Likelihood of Approval (LOA) opinions successfully predicted 63% of catalyst outcomes that occurred in Q2 2016.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Amyotrophic Lateral Sclerosis (ALS)
Anti-Parasitic and Anti-Protozoal
Cardiac Valve Surgery
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
Chronic Pain
Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI)
Crohn's Disease
Drug Toxicity
Dry Eye (Ophthalmology)
Dyslipidemia / Hypercholesterolemia
Glaucoma / Ocular Hypertension (Ophthalmology)
Hemostasis
Hyperparathyroidism (Secondary)
Melanoma
Non-Alcoholic Steatohepatitis (NASH)
Opioid Induced Constipation (OIC)
Psoriasis
Rheumatoid Arthritis (RA)
Sarcoma - Unspecified

 Additional Resources: